TippingPoint Biosciences

TippingPoint Biosciences has developed a proprietary small molecule screening platform aimed at treating diseases related to dysfunctional DNA packaging (chromatin). The platform uses a novel method of condensate biology to overcome a major hurdle and effectively model chromatin behavior outside of the body, which unlocks the ability to discover and screen drugs for chromatin-related diseases that spare healthy cells. TippingPoint Biosciences both develops their own therapies and provides pharmaceutical companies access to a platform that enhances the potential for discovering first-in-class drugs, offering a competitive edge in drug development.